Back to search

Netherlands· NL-c203fd1bfa37

AGAMREE 40 mg/ml suspensie voor oraal gebruik

A vamorolone product containing vamorolon, registered in Netherlands by Santhera Pharmaceuticals (Deutschland) GmbH. The same ATC class is registered in 11 of our 19 countries.

ATC H02AB18

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedAGAMREE 40 mg/ml suspensie voor oraal…ATCH02AB18REGISTER NO.NL-c203fd1bfa37PACKS LISTED1CHECKEDSeptember 29, 2026

Where it is registered

Vamorolone is registered in 11 of 19 countries.

Countries holding a registration under ATC H02AB18 (vamorolone), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 7 of them publish a price we can compare per daily dose

Vamorolone · ATC H02AB18

11 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
VAMOROLON
Manufacturer
Santhera Pharmaceuticals (Deutschland) GmbH
Country
Netherlands (NL)
ATC code
H02AB18
ATC class
Vamorolone
Defined daily dose
0.24 g, O
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/23/1776

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/b568c6d2-91ad-4c91-a839-f85e50a295fc
GET /v1/drugs/b568c6d2-91ad-4c91-a839-f85e50a295fc?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Suspensie voor oraal gebruik",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/agamree-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Vamorolone",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp130593",
  "excipients": [
    "CITROENZUUR 1-WATER (E 330)",
    "DINATRIUMWATERSTOFFOSFAAT 0-WATER (E 339)",
    "GLYCEROL (E 422)",
    "NATRIUMBENZOAAT (E 211)",
    "SINAASAPPELSMAAKSTOF",
    "SUCRALOSE (E 955)",
    "WATER, GEZUIVERD",
    "XANTHAANGOM (E 415)",
    "ZOUTZUUR (E 507)"
  ],
  "substances": [
    "VAMOROLON"
  ],
  "leaflet_url": null,
  "authorised_at": "2023/12/14",
  "procedure_number": "EMEA/H/C/005679",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/23/1776",
  "additional_monitoring": "Y"
}

See everything about vamorolone.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.